Published On: Wed, Oct 19th, 2016

Analyst Coverage: Laboratory Corporation Of America Holdings (NYSE:LH)


Recently stock market analysts have updated their consensus ratings on shares of Laboratory Corporation of America Holdings (NYSE:LH).

Most recent broker ratings

09/15/2016 – Laboratory Corporation of America Holdings had its “neutral” rating reiterated by analysts at Mizuho. They now have a USD 145 price target on the stock.

09/09/2016 – Citigroup began new coverage on Laboratory Corporation of America Holdings giving the company a “neutral” rating. They now have a USD 156 price target on the stock.

08/29/2016 – Laboratory Corporation of America Holdings had its “overweight” rating reiterated by analysts at Barclays. They now have a USD 155 price target on the stock.

07/27/2016 – Laboratory Corporation of America Holdings had its “buy” rating reiterated by analysts at Evercore ISI. They now have a USD 155 price target on the stock.

06/09/2016 – Laboratory Corporation of America Holdings had its “outperform” rating reiterated by analysts at Credit Suisse. They now have a USD 143 price target on the stock.

04/26/2016 – Laboratory Corporation of America Holdings had its “hold” rating reiterated by analysts at Jefferies. They now have a USD 131 price target on the stock.

04/26/2016 – Laboratory Corporation of America Holdings had its “neutral” rating reiterated by analysts at UBS. They now have a USD 125 price target on the stock.

04/26/2016 – Laboratory Corporation of America Holdings had its “buy” rating reiterated by analysts at Canaccord Genuity. They now have a USD 140 price target on the stock.

02/19/2016 – Laboratory Corporation of America Holdings had its “sector perform” rating reiterated by analysts at RBC Capital. They now have a USD 130 price target on the stock.

12/22/2015 – Laboratory Corporation of America Holdings had its “neutral” rating reiterated by analysts at Goldman Sachs. They now have a USD 125 price target on the stock.

12/17/2015 – Laboratory Corporation of America Holdings was downgraded to “hold” by analysts at Stifel Nicolaus.

10/26/2015 – Laboratory Corporation of America Holdings had its “outperform” rating reiterated by analysts at William Blair.

06/15/2015 – KeyBanc began new coverage on Laboratory Corporation of America Holdings giving the company a “overweight” rating. They now have a USD 143 price target on the stock.

05/24/2015 – Laboratory Corporation of America Holdings was upgraded to “buy” by analysts at Zacks. They now have a USD 135 price target on the stock.

04/28/2015 – Laboratory Corporation of America Holdings had its “overweight” rating reiterated by analysts at JP Morgan. They now have a USD 144 price target on the stock.

Laboratory Corporation of America Holdings has a 50 day moving average of 136.74 and a 200 day moving average of 131.71. The stock’s market capitalization is 14.15B, it has a 52-week low of 97.79 and a 52-week high of 141.32.

The share price of the company (NYSE:LH) was up +1.72%, with a high of 138.95during the day and the volume of Laboratory Corporation of America Holdings shares traded was 681650.

Laboratory Corporation of America Holdings is a healthcare diagnostics company. The Company, together with its subsidiaries, is engaged in providing clinical laboratory services and drug development support. The Company operates through two segments: LabCorp Diagnostics (LCD) and Covance Drug Development (CDD). The Company’s LCD segment is an independent clinical laboratory business that consists of a network of approximately 40 primary laboratories and approximately 1,700 patient service centers (PSCs) along with a network of branches and STAT laboratories, which offer a menu of routine and frequently ordered tests. LCD offers a menu of over 4,700 tests, such as blood chemistry analyses, urinalyses, blood cell counts and thyroid tests. Its CDD segment offers drug development services, and provides a range of drug development solutions across the world, primarily to companies in the pharmaceutical and biotechnology industries.